Rebelos E

Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study.

Oldgren J, Laurila S, Åkerblom A, ..., Oscarsson J, Nuutila P

Diabetes Obes Metab 23 (7) 1505-1517 [2021-07-00; online 2021-03-12]

Olof Eriksson SciLifeLab Fellow